Establishment Labs Holdings (Nasdaq:ESTA) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ESTA Stoklara Genel Bakış

Bir tıbbi teknoloji şirketi olan Establishment Labs Holdings Inc. estetik ve rekonstrüktif plastik cerrahi için tıbbi cihazlar üretmekte ve pazarlamaktadır.

Şirket hakkında

ESTA temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 49.1% daha düşük bir oranda işlem görüyor

Kazançların yılda 61.95% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda dalgalı hisse senedi fiyatı

1 yıldan az nakit akışı var

Hissedarlar geçen yıl sulandırıldı

Establishment Labs Holdings Inc. Rakipler

Bioventus

NasdaqGS:BVS

US$1.0b

STAAR Surgical

NasdaqGM:STAA

US$1.6b

Avanos Medical

NYSE:AVNS

US$989.3m

Meridian Bioscience

NasdaqGS:VIVO

US$1.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Establishment Labs Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$42.29
52 Haftanın En Yüksek Seviyesi	US$60.12
52 Haftanın En Düşük Seviyesi	US$16.96
Beta	1.2
11 Aylık Değişim	-2.92%
3 Aylık Değişim	-6.99%
1 Yıllık Değişim	21.04%
33 Yıllık Değişim	-44.79%
5 Yıllık Değişim	129.96%
Halka arzdan bu yana değişim	70.87%

Son Haberler & Güncellemeler

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

Sep 23

Recent updates

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

Sep 23

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Aug 11

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Jul 23

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Apr 17

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Dec 14

Establishment Labs drops 18% after new short report from Hindenburg Research

Oct 19

Establishment Labs: Flat Earnings, Return On Investment Keep Buyers At Bay

Sep 24

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Sep 04

Establishment Labs started at buy at B Riley on breast implants

Aug 24

Health Check: How Prudently Does Establishment Labs Holdings (NASDAQ:ESTA) Use Debt?

Feb 23

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Debt Sensibly?

Sep 25

Hissedar Getirileri

	ESTA	US Medical Equipment	US Pazar
7D	9.0%	0.6%	1.1%
1Y	21.0%	26.9%	36.0%

Getiri vs. Endüstri: ESTA geçen yıl % 22.6 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: ESTA geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ESTA's price volatile compared to industry and market?
ESTA volatility
ESTA Average Weekly Movement	10.6%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ESTA hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ESTA 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2004	857	Juan Chacon Quiros	www.establishmentlabs.com

Bir tıbbi teknoloji şirketi olan Establishment Labs Holdings Inc. estetik ve rekonstrüktif plastik cerrahi için tıbbi cihazlar üretmekte ve pazarlamaktadır. Şirket öncelikle Motiva Implants markası altında silikon jel dolgulu meme implantları sunmaktadır. Ayrıca Motiva Ergonomix ve Motiva Ergonomix2 yerçekimine duyarlı yuvarlak yumuşak silikon jel dolgulu meme implantları; ve bir meme dokusu genişletici olan Motiva Flora Tissue Expander sunmaktadır.

Establishment Labs Holdings Inc. Temel Bilgiler Özeti

Establishment Labs Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ESTA temel i̇stati̇sti̇kler
Piyasa değeri	US$1.20b
Kazançlar(TTM)	-US$83.20m
Gelir(TTM)	US$151.35m

7.8x

P/S Oranı

-14.2x

F/K Oranı

ESTA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ESTA gelir tablosu (TTM)
Gelir	US$151.35m
Gelir Maliyeti	US$51.40m
Brüt Kâr	US$99.95m
Diğer Giderler	US$183.15m
Kazançlar	-US$83.20m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.98
Brüt Marj	66.04%
Net Kâr Marjı	-54.97%
Borç/Özkaynak Oranı	430.3%

ESTA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ESTA Stoklara Genel Bakış

Ödüller

Risk Analizi

Establishment Labs Holdings Inc. Rakipler

NasdaqGS:BVS

US$1.0b

NasdaqGM:STAA

US$1.6b

NYSE:AVNS

US$989.3m

NasdaqGS:VIVO

US$1.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Establishment Labs Holdings Inc. Announces the First Patients in the United States Have Successfully Undergone Breast Augmentation with Motiva Implants

New minor risk - Share price stability

Establishment Labs Holdings Inc. Receives U.S. FDA Approval for Motiva Implants

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

No longer forecast to breakeven

Consensus EPS estimates fall by 25%

Recent updates

Establishment Labs Holdings Inc. Announces the First Patients in the United States Have Successfully Undergone Breast Augmentation with Motiva Implants

New minor risk - Share price stability

Establishment Labs Holdings Inc. Receives U.S. FDA Approval for Motiva Implants

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

No longer forecast to breakeven

Consensus EPS estimates fall by 25%

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q2, 2024 Results on Aug 06, 2024

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Founder notifies of intention to sell stock

Insufficient new directors

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q1, 2024 Results on May 08, 2024

Establishment Labs Holdings Inc., Annual General Meeting, May 24, 2024

Establishment Labs Holdings Inc. announced delayed annual 10-K filing

Price target increased by 10% to US$52.86

Full year 2023 earnings: EPS exceeds analyst expectations

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q4, 2023 Results on Feb 28, 2024

Establishment Labs: Catalysts Supporting A Perky Outlook

Establishment Labs Holdings Inc. announced that it has received $49.999102 million in funding from a group of investors

Establishment Labs Holdings Inc. announced that it expects to receive $50 million in funding

Establishment Labs Holdings Inc. Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander

Forecast to breakeven in 2026

Is Establishment Labs Holdings (NASDAQ:ESTA) A Risky Investment?

Chairman of the Board recently bought US$110k worth of stock

Chairman of the Board exercised options to buy US$5.8m worth of stock.

Consensus revenue estimates fall by 18%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2023

New minor risk - Share price stability

Establishment Labs Holdings Inc. to Report Q3, 2023 Results on Nov 07, 2023

Establishment Labs Announces FDA Clearance of Motiva Flora Smoothsilk Tissue Expander

Price target decreased by 7.7% to US$89.38

Est Establishment Labs Holdings Inc. Announces Two-Year Mia Femtech Clinical Results and the Launch of Zen at 8th World Symposium on Ergonomic Implants

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2023

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Establishment Labs Holdings Inc. to Report Q2, 2023 Results on Aug 08, 2023

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.48 loss per share (vs US$0.24 loss in 1Q 2022)

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Insider recently sold US$254k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Establishment Labs Holdings Inc. to Report Q4, 2022 Results on Feb 27, 2023

Establishment Labs Holdings Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2022

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Establishment Labs Holdings Inc. Appoints Paul D. Rodio as Chief Operating Officer

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Establishment Labs Holdings Inc. Provides Earnings Guidance for the Year 2022

Establishment Labs Holdings Inc. to Report Q3, 2022 Results on Nov 07, 2022

Establishment Labs drops 18% after new short report from Hindenburg Research

Price target increased to US$97.40

Establishment Labs: Flat Earnings, Return On Investment Keep Buyers At Bay

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Establishment Labs started at buy at B Riley on breast implants